17.05.2013
Fresenius Medical Care AG & Co. KGaA DE0005785802
DGAP-News: Fresenius Medical Care AG & Co. KGaA: Announcement pursuant to Article 4 para. 2 of the Commission Regulation (EC) No. 2273/2003
DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Share
Buyback/Share Buyback
Fresenius Medical Care AG & Co. KGaA: Announcement pursuant to Article
4 para. 2 of the Commission Regulation (EC) No. 2273/2003
17.05.2013 / 17:35
---------------------------------------------------------------------
May 17, 2013
Announcement pursuant to Article 4 para. 2 of the Commission Regulation
(EC) No. 2273/2003
Fresenius Medical Care commences announced share buyback program
The share buyback program announced by Fresenius Medical Care AG & Co. KGaA
(Fresenius Medical Care or the 'company') in its ad hoc disclosure on April
4, 2013 will commence on May 20, 2013. For the first time, Fresenius
Medical Care thereby makes use of the authorization pursuant to Section 71
para. 1 no. 8 of the German Stock Corporation Act to acquire own shares as
granted by the General Meeting of the company on May 12, 2011. In the
context of this share buyback program, ordinary shares of Fresenius Medical
Care (ISIN DE0005785802) in the total amount of up to EUR 385 million
(approximately $ 500 million) shall be repurchased in the period from May
20, 2013 until and including November 20, 2013. Based on the closing
auction share price of the ordinary share in the XETRA trading system of
EUR 53.04 as of 16 May 2013, this corresponds to a total volume of
approximately 7.0 million ordinary shares and therefore approximately 2.3%
of the registered share capital of Fresenius Medical Care. The share
buyback is in the best interest of the company and its shareholders. The
own shares acquired by the company will be used to serve the sole purposes
of either reducing the registered share capital of the company by
cancellation of the acquired own shares, or fulfilling employee
participation programs of the company.
The shares will exclusively be repurchased on the stock exchange by way of
the XETRA trading system. Pursuant to the requirements of the acquisition
authorization granted by the General Meeting of the company on May 12,
2011, the price per share paid by the company (excluding ancillary
acquisition costs) must not exceed or fall short of the market price of
(ordinary) shares of the company by more than 10% as determined by the
opening auction in the XETRA trading system on the respective stock
exchange trading day.
The buyback of shares will be effected in accordance with the safe harbor
provisions pursuant to Sections 14 para. 2, 20a para. 3 of the German
Securities Trading Act in conjunction with the provisions of the Commission
Regulation (EC) No 2273/2003 of December 22, 2003 implementing Directive
2003/6/EC of the European Parliament and of the Council as regards
exemptions for buyback programs and stabilization of financial instruments
(EC-Reg). The buyback program will be conducted on behalf and on account of
the company under the lead-management of a financial institution which
makes its trading decisions in relation to the purchase of the shares of
Fresenius Medical Care independently of, and without influence by, the
company. The financial institution particularly committed itself vis-à-vis
Fresenius Medical Care to comply with the requirements of the acquisition
authorization as granted by the General Meeting of the company on May 12,
2011 as well as the trading conditions pursuant to Article 5 para. 1 and
para. 2 EC-Reg when executing the share buyback program. Pursuant to
Article 5 para. 1 EC-Reg, the issuer must not purchase shares in the
context of the share buyback program at a price higher than the higher of
the price of the last independent trade and the highest current independent
bid on the trading venues where the purchase is carried out; at the same
time, no more than 25% of the average daily volume of the shares in any one
day on the regulated market on which the purchase is carried out may be
purchased pursuant to Art. 5 para. 2 EC-Reg in the context of the share
buyback program. The average daily volume of the shares in this context is
based on the average daily volume traded in the 20 trading days preceding
the date of purchase.
Fresenius Medical Care will regularly report on the executed transactions
pursuant to Sections 14 para. 2, 20a para. 3 of the German Securities
Trading Act in conjunction with Article 4 para. 4 EC-Reg- in the 'Investor
Relations' section on the Fresenius Medical Care website, available at
www.fmc-ag.com.
Fresenius Medical Care AG & Co. KGaA
Represented by Fresenius Medical Care Management AG
Represented by its Management Board
Bad Homburg v.d.H., May 17, 2013
Fresenius Medical Care is the world's largest integrated provider of
products and services for individuals undergoing dialysis because of
chronic kidney failure, a condition that affects more than 2.3 million
individuals worldwide. Through its network of 3,180 dialysis clinics in
North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius
Medical Care provides dialysis treatment to 261,648 patients around the
globe. Fresenius Medical Care is also the world's leading provider of
dialysis products such as hemodialysis machines, dialyzers and related
disposable products. Fresenius Medical Care AG & Co. KGaA is listed on the
Frankfurt Stock Exchange (FME, FME 3) and on the New York Stock Exchange
(FMS).
For more information about Fresenius Medical Care, visit the company's
website at www.fmc-ag.com.
Disclaimer
This release contains forward-looking statements that are subject to
various risks and uncertainties. Actual results could differ materially
from those described in these forward-looking statements due to certain
factors, including changes in business, economic and competitive
conditions, regulatory reforms, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties are
detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the
U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co.
KGaA does not undertake any responsibility to update the forward-looking
statements in this release.
End of Corporate News
---------------------------------------------------------------------
17.05.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Fresenius Medical Care AG & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
Phone: +49 (0) 6172- 609 2525
Fax: +49 (0) 6172- 609 2301
E-mail: [email protected]
Internet: www.fmc-ag.de
ISIN: DE0005785802, DE0005785836,
WKN: 578580, 578583
Indices: DAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart; Terminbörse EUREX; NYSE
End of News DGAP News-Service
---------------------------------------------------------------------
211672 17.05.2013
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Fresenius Medical Care AG & Co. KGaA ISIN: DE0005785802 können Sie bei EQS abrufen
Medtech , 578580 , FME , XETR:FME